Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Poa compressa pollen is a biological allergen extract derived from the pollen of the *Poa compressa* plant, commonly known as Canada bluegrass or flat-stemmed bluegrass. It is primarily utilized as a diagnostic agent in allergenic skin testing (such as skin prick or intradermal tests) to identify individuals with IgE-mediated hypersensitivity to this specific grass species. Additionally, it is used in allergen immunotherapy (AIT), where patients are administered gradually increasing doses of the extract to induce immunological tolerance and reduce symptoms of allergic rhinitis and conjunctivitis. The extract contains a complex mixture of proteins and glycoproteins that act as allergens, specifically cross-linking allergen-specific IgE antibodies bound to high-affinity receptors on mast cells and basophils, thereby triggering the release of inflammatory mediators.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on poa compressa pollen.